<DOC>
	<DOCNO>NCT01486862</DOCNO>
	<brief_summary>This trial conduct North America . The aim trial investigate efficacy biphasic insulin aspart 30 subject type 2 diabetes achieve glycaemic target OADs ( oral anti-diabetic drug ) .</brief_summary>
	<brief_title>Efficacy Biphasic Insulin Aspart 30 Subjects With Type 2 Diabetes Failing OADs</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 2 diabetes mellitus least 12 month HbA1c 7.514.5 % ( inclusive ) screen Insulin na√Øve An antidiabetic regimen stable least 3 month prior screen An antidiabetic regimen include minimum 2 OADs Use insulin preparation within past 6 month Active proliferative retinopathy maculopathy require treatment within 6 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>